Alkermes plcALKSNASDAQ

52-Week Range25-36

25.17Current 27.4236.32

Want to monitor ALKS?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.

Manufacturing

Pharmaceutical Preparation Manufacturing

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

News

J&J Expands New Drug Portfolio With Icotyde's FDA Approval

Will Kraft Heinz's NFL Deal Strengthen Its Growth Recovery Plan?

Can KDP Sustain Its Growth Amid Cost Pressures & Coffee Headwinds?

Here's Why Investors Should Hold Western Union Stock for Now

3 AgTech & Food Innovation Picks Riding on Structural Growth Trends

Visa's Ingenico Tie-Up: Expanding Beyond the Payment Layer

ProWood Backs the Next Generation of Home Developers, Commits to Filling Critical Knowledge and Training Gaps with NHCA Alliance

Micron Slips 4%: NVIDIA's HBM Supplier Just Posted Record Results, So Why Is It Falling?

Two Harbors: The Merger That Might Not Be

GROUP BNP PARIBAS: Release of the English version of the Universal Registration Document and Annual Financial Report 2025

Tombill Mines Announces Appointment of Alicia Grimes as New Corporate Secretary

TAT Technologies Ltd. (TATT) Q4 2025 Earnings Call Transcript

Gulf Keystone Petroleum Limited (GUKYF) Q4 2025 Earnings Call Transcript

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why

KBR Lands Libya Deal With Zallaf: Is the Expansion a New Growth Lever?

Globale Online (GLBE) Upgraded to Strong Buy: Here's Why

What Makes MYR Group (MYRG) a Strong Momentum Stock: Buy Now?

All You Need to Know About International Consolidated Airlines Group (ICAGY) Rating Upgrade to Strong Buy

Adecoagro (AGRO) Upgraded to Strong Buy: Here's What You Should Know

About